Danforth Advisors, LLC has acquired Elite BioPharma Consulting, Inc., a move designed to broaden the range of its newly formed development strategy and sperations (DS&O) practice and supporting life science companies in the advancement of preclinical and clinical programs without the burden of fixed costs.

Founders Jill Bossi, senior vice president clinical operations, Shawna Evans, vice president clinical strategy, and Connacht Peterson, senior vice president, clinical development, will continue to lead the Elite team.

With the acquisition of Elite, Danforth becomes the single provider of enterprise-wide managed functions – from corporate to clinical – tailored to support life science companies at all stages of development.  

The Elite acquisition adds the following capabilities to Danforth’s DS&O practice: clinical development operations; clinical project and trial management; clinical monitoring; program management; regulatory affairs and medical writing.

“Our vision from inception was to become a variable resource exclusively for life science companies, aggregating cross-functional specialists as an alternative to over-building internal resources – a diversion of capital away from the science,” said Gregg Beloff, co-founder and managing director of Danforth. “Our model has proven effective on the general & administrative side for hundreds of life science companies – many of whom we supported from early stages through IPO or acquisition and beyond. With our expansion into DS&O and the acquisition of Elite, we have taken our biggest step yet towards making our full vision a reality.”

“The Elite team applies deeply rooted expertise and leadership skills to drive clinical development programs forward. We offer comprehensive consulting services through every stage of product development,” said Shawna Evans, founder, and co-president of Elite. “Danforth is a natural fit for our team and positions us within a large ecosystem of strategically integrated services dedicated to bringing novel therapies and devices to market.”